Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Best Peptides for Muscle Growth (2026)

Q: What is the best peptide for muscle growth?

There is no single peptide with strong controlled human evidence as the best muscle-growth compound. IGF-1 LR3 is the most direct anabolic-signalling candidate in preclinical models, CJC-1295 + Ipamorelin is the most-studied GH-secretagogue pairing, and Tesamorelin carries the strongest human body-composition data of the group. Each is evaluated for a different research question, not ranked against one shared, proven outcome.

An evidence-ranked research guide - mechanism first, human data second. Research use only; not for human use.

What Is the Best Peptide for Muscle Growth?

For muscle-growth research, IGF-1 LR3 provides one of the most direct models of IGF-1 signalling, while CJC-1295 + Ipamorelin is widely studied around upstream GH signalling. Tesamorelin has a stronger human body-composition evidence base in specific clinical populations. No research peptide has strong controlled evidence establishing it as the universally best muscle-building compound in healthy humans.

Best Peptides for Muscle Growth: Quick Ranking

Rank Compound Primary Research Role Evidence Level Best Research Fit 1 IGF-1 LR3 Direct IGF-1 signalling Mechanistic / preclinical-heavy Direct anabolic signalling 2 CJC-1295 + Ipamorelin GH / IGF-1 axis Human pathway evidence GH secretagogue research 3 Tesamorelin GHRH analogue Human clinical evidence Body-composition research 4 Local IGF signalling Primarily preclinical Muscle adaptation 5 Hexarelin GH secretagogue Limited human evidence GH-response research 6 Sermorelin GHRH signalling Human pharmacology GH-axis research 7 BPC-157 + TB-500 Recovery biology Primarily preclinical Tissue-recovery research

Rank reflects how directly and how often each compound appears in muscle-growth research discussion - not proven effectiveness in humans. See the evidence grading below for what each Evidence Level actually means.

How New-U Grades Muscle-Growth Evidence

We grade every compound on this page against one scale, so "evidence" always means the same thing whether we are talking about IGF-1 LR3 or Tesamorelin.

Grade Evidence A Controlled human muscle/hypertrophy outcome data B Human body-composition outcome data C Human hormonal or pharmacodynamic evidence D Animal evidence E Cell, mechanistic or theoretical evidence

No compound on this page currently reaches Grade A. That gap - mechanism far ahead of proven human hypertrophy outcomes - is the honest state of muscle-growth peptide research in 2026.

How to read this list. "Best" here means most-studied and most-discussed in muscle-growth research - not a recommendation, a dose, or a promise of results. We describe what each compound does mechanistically, grade the human evidence honestly, and say where the evidence stops. There are no protocols on this page.

1. IGF-1 LR3

How IGF-1 LR3 affects muscle-growth signalling

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is the compound the muscle-growth literature returns to most. IGF-1 is the downstream mediator of many of growth hormone's anabolic effects; the LR3 modification lowers its binding to IGF-binding proteins and extends the active half-life dramatically versus native IGF-1. In cell and animal models it drives satellite-cell activation, myoblast proliferation and protein synthesis - the core hypertrophy signals. IGF-1 signalling is also a cell-proliferation pathway, which is why it is studied carefully rather than used casually.

What human evidence exists?

Controlled human muscle-growth trials of the LR3 research analogue are essentially absent. Most human IGF-1 data comes from native IGF-1 physiology and clinical-deficiency literature, not the LR3 modification specifically. See our IGF-1 DES vs LR3 comparison for the analogue detail, and our dedicated IGF-1 LR3 vs CJC-1295 + Ipamorelin breakdown for how its evidence stacks up against the GH-secretagogue route.

Human Muscle Evidence: D. Cell and animal-model signalling data are well described; controlled human hypertrophy evidence for the LR3 analogue itself is not established.

2. CJC-1295 + Ipamorelin

Why CJC-1295 and Ipamorelin are researched together

CJC-1295 is a GHRH analogue acting upstream on the pituitary; Ipamorelin is a selective GHRP acting on the ghrelin receptor. Because the two act on different receptors with non-overlapping mechanisms, pre-clinical work shows the pair evoking a GH pulse larger than either compound alone - the standard reason the literature studies them together rather than separately. Full mechanism detail: CJC-1295 & Ipamorelin research guide.

Does CJC-1295 + Ipamorelin build muscle?

No controlled human hypertrophy trial exists for this specific pairing. What is published is human pharmacodynamic data on GH-pulse amplitude and timing - evidence about hormone release, not evidence that the combination changes muscle mass. For the full side-by-side against the direct-signalling route, see IGF-1 LR3 vs CJC-1295 + Ipamorelin: Which Has Better Muscle-Growth Evidence?

Human Muscle Evidence: C. Human hormonal/pharmacodynamic data exist for both molecules; controlled hypertrophy evidence for the pairing is not established.

3. Tesamorelin

Does Tesamorelin increase muscle mass?

Tesamorelin is a stabilised, more potent GHRH analogue than sermorelin, with dedicated human trial data and FDA approval in a narrow clinical indication (reducing visceral adipose tissue in HIV-associated lipodystrophy). Some of that trial work also tracked IGF-1 and, in places, lean body mass as a secondary endpoint - giving Tesamorelin the strongest human clinical dataset of any compound on this page. That is body-composition evidence in a specific clinical population, not a controlled trial of muscle-hypertrophy outcomes in healthy trained adults. See Tesamorelin vs Sermorelin for the GHRH-analogue comparison.

Human Muscle Evidence: B. Human body-composition outcome data exist in a defined clinical population; controlled hypertrophy evidence in healthy trained humans is not established.

4. PEG-MGF

(Mechano Growth Factor) is a splice variant of IGF-1 produced locally in muscle after mechanical overload - the body's own "you just trained, start repairing" signal. It is studied for satellite-cell activation and local repair at the site of damage. Native MGF is extremely short-lived, so PEG-MGF - a PEGylated, longer-acting version - is the form most research uses. Like IGF-1 LR3, the mechanism is well described in models and the human hypertrophy evidence is thin.

Human Muscle Evidence: D. Animal-model overload/repair data are the primary evidence base; controlled human hypertrophy trials are not established.

5. Hexarelin

Hexarelin is one of the more potent GHRP-class ghrelin-receptor agonists, and it uniquely engages the CD36 receptor studied in cardiac models. It produces a strong acute GH release with faster desensitisation and less selectivity than Ipamorelin. Compare it directly in Hexarelin vs CJC-1295 and Hexarelin vs Ipamorelin. The related original GHRPs, GHRP-2 and GHRP-6, are also strong GH releasers studied alongside Hexarelin, though both raise cortisol/prolactin more than Ipamorelin and GHRP-6 carries a pronounced ghrelin-driven appetite effect.

Human Muscle Evidence: C. Human GH-release pharmacodynamic data exist; controlled hypertrophy evidence does not.

6. Sermorelin

Sermorelin is the short GHRH(1-29) fragment - the same active sequence CJC-1295 builds on with stability modifications. It acts upstream on the pituitary's GHRH receptor and has a long history of human pharmacology data (it was previously an approved GHRH product before discontinuation). See Ipamorelin vs Sermorelin for the GHRH-vs-GHRP contrast.

Human Muscle Evidence: C. Human GHRH-axis pharmacology is well documented; controlled muscle-hypertrophy evidence is not.

Peptides for Muscle Growth vs Recovery

Not every compound in this research area is trying to build tissue. BPC-157 and TB-500 - together nicknamed the "Wolverine stack" - are studied for angiogenesis, fibroblast migration, cell motility and soft-tissue repair in pre-clinical models. They belong on an honest muscle-growth research map because recovery is the rate-limiter for hypertrophy, not because either compound is an anabolic signaller like IGF-1 LR3 or a GH secretagogue like CJC-1295. Treat this pair as recovery-support research, not muscle-building research.

Human Muscle Evidence: D. Extensive animal-model soft-tissue and repair data exist for both peptides; they are not studied as muscle-hypertrophy agents, and controlled human muscle-growth evidence does not apply to this pair.

Best Peptide for Lean Muscle Growth

"Lean muscle growth" searches point at the same compound set covered above, not a separate category. IGF-1 LR3 remains the most direct anabolic-signalling candidate; CJC-1295 + Ipamorelin remains the most-studied upstream route through the GH/IGF-1 axis. Neither has controlled human evidence specific to lean-mass outcomes, so there is no single answer here that the research supports - see the FAQ below for the direct version of this question.

Best Peptide Stack for Muscle Growth

In research terms, a "stack" is simply two compounds studied together because their mechanisms are complementary rather than redundant - the GHRH + GHRP pairing above (CJC-1295 + Ipamorelin) is the clearest example, and IGF-1 LR3 is sometimes discussed alongside the GH-axis compounds because it sits downstream of the same signalling cascade. We cover the mechanistic reasoning for these pairings, without dosing or protocol detail, in our dedicated Best Peptide Stack for Muscle Growth: What the Research Shows.

IGF-1 LR3 vs CJC-1295 + Ipamorelin

These two represent the field's two main strategies: IGF-1 LR3 supplies the anabolic signal directly, while CJC-1295 + Ipamorelin raises the body's own GH/IGF-1 output upstream. Neither has controlled human hypertrophy data, but the type of evidence behind each is different - preclinical signalling data for IGF-1 LR3 versus human hormonal pharmacodynamic data for the secretagogue pair. Full comparison: IGF-1 LR3 vs CJC-1295 + Ipamorelin: Which Has Better Muscle-Growth Evidence?

Peptides for Muscle Growth and Fat Loss

A handful of compounds appear in both the muscle-growth and fat-loss research conversations, but usually for different mechanistic reasons. Tesamorelin has the clearest overlap - its human trial data is built around visceral-fat reduction, with IGF-1/lean-mass tracked secondarily, which is exactly the body-composition angle referenced above. GH-axis secretagogues more broadly are studied for lipolytic signalling alongside anabolic signalling in some models, though - as with muscle outcomes - controlled human recomposition trials for the research-compound versions are largely missing. For the fat-loss-specific compound set, see our Best Peptides for Weight Loss Research guide.

Muscle Growth Peptides: Human Evidence vs Animal Research

The grading table above exists because "evidence" gets flattened into one word far too often in this space. Mechanism (a receptor pathway shown in cells) is not the same as animal data (a rodent or other model outcome), which is not the same as human pharmacodynamics (a hormone-release measurement in people), which is not the same as human body-composition data (a measured change in fat or lean mass), which is not the same as an actual controlled hypertrophy outcome (measured muscle growth in a trial). Every compound on this page sits somewhere in that chain - none has reached the final link. Reading the evidence honestly means naming which link a given claim is actually standing on.

How New-U Evaluates Muscle-Growth Research Compounds

Every grade and every mechanism claim on this page is checked against the same evaluation criteria, in this order:

Human outcome evidence - is there a controlled trial measuring muscle growth itself, in humans?

Human body-composition evidence - is there human trial data on fat mass or lean mass, even if hypertrophy was not the primary endpoint?

Human pharmacodynamic evidence - is there human data on the hormone or signalling response the compound is meant to trigger?

Animal evidence - what do rodent or other animal models show, and in which tissue or injury context?

Cellular/mechanistic evidence - what receptor pathway or in-vitro signalling result is the compound's rationale built on?

Molecular identity - is the compound's sequence, modification and molecular weight clearly documented and distinguishable from closely related analogues?

Published research availability - how much peer-reviewed literature exists, and how recent is it?

Analytical verification / COA availability - can purity and identity be independently confirmed per batch? See How to Read a Certificate of Analysis.

Regulatory status - is the compound approved for any indication, investigational, or unregulated as a research reagent?

WADA status where relevant - is the compound prohibited in sanctioned competition, and under which category?

Mechanism is not outcome. Every compound here has a real signalling pathway - but rigorous long-term human hypertrophy trials for the research-compound versions are largely missing, and much GH-axis data comes from clinical deficiency or narrow indication populations, not healthy trained subjects. These are research-use-only reagents supplied by New-U for laboratory work, and nothing here is dosing guidance or medical advice. Essentially the entire category is WADA-prohibited (S2) - off-limits for any tested athlete. Note also that MK-677 (ibutamoren) is often listed for muscle growth but is not stocked by New-U and is a non-peptide small molecule, not a peptide.

Frequently Asked Questions

What is the strongest peptide for muscle growth?

"Strongest" usually means potency at the receptor, not proven muscle-building power. IGF-1 LR3 has the most direct anabolic-signalling mechanism among catalogued research peptides, engaging IGF-1 receptor pathways tied to satellite-cell activation and protein synthesis in preclinical models. That mechanistic strength has not been replicated in controlled human hypertrophy trials, so "strongest" describes signalling potency in models, not a demonstrated real-world effect.

What peptide is best for building lean muscle?

No catalogued research peptide has controlled human evidence for lean-muscle outcomes specifically. IGF-1 LR3 models direct anabolic signalling; CJC-1295 + Ipamorelin studies upstream GH/IGF-1 release; Tesamorelin has human body-composition data, though its trial population and endpoint (visceral fat, not lean-mass hypertrophy) differ from a bodybuilding context. Lean-muscle claims for any of these compounds outrun the current human evidence.

Does CJC-1295 and Ipamorelin build muscle?

No controlled human hypertrophy trial exists for this specific pairing. CJC-1295 (a GHRH analogue) and Ipamorelin (a selective GHRP) are studied together because they act on separate receptors and produce a larger GH pulse in combination than either alone. That is human pharmacodynamic evidence about hormone release, not evidence that the pairing changes muscle mass in trained or untrained people.

Is IGF-1 LR3 better for muscle growth?

"Better" implies a human comparison that has not been run. IGF-1 LR3 has the most direct mechanistic link to muscle-growth signalling of any compound on this page - it is a long-acting IGF-1 analogue tied to satellite-cell and protein-synthesis pathways in cell and animal models. Controlled human trials of the LR3 analogue itself are not established, so the comparison stays at the mechanism level, not a proven-outcome level.

Does Tesamorelin build muscle?

Tesamorelin's strongest evidence is body composition, not muscle hypertrophy specifically. As a stabilised GHRH analogue, it is FDA-approved in a narrow clinical indication for reducing visceral adipose tissue, with trial data also tracking IGF-1 and, in some studies, lean body mass as a secondary measure. That is a real human clinical dataset, but it is not a controlled trial of muscle-growth outcomes in healthy trained adults.

What peptides are studied in bodybuilding research?

Bodybuilding-adjacent literature discusses three groups: direct anabolic signallers (IGF-1 LR3/PEG-MGF), GH-axis secretagogues (CJC-1295, Ipamorelin, Hexarelin, Sermorelin, Tesamorelin, GHRP-2/6), and the recovery pair BPC-157 + TB-500, which supports training load rather than building tissue directly. See our peptides & bodybuilding research map for how each group is studied. All are research-use-only, and most fall under WADA's S2 prohibited category.

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research